Evidence map›Paper›PMID 42316940›Full record

ArticleEuropean journal of breast health2026

Safety and Early Outcomes of Immediate Autologous Breast Reconstruction in Advanced Breast Cancer: An Indian Experience.

Meenu Jose, Shivani Sable, Tabassum Wadasadawala, Rajiv Sarin, Rima Pathak, Revathy Krishnamurthy, Shalaka Joshi, Vinaykant Shankhdhar, Dushyant Jaiswal, Saumya Mathews and 1 more

Abstract read
In one paragraph

Article in European journal of breast health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Meenu JoseTata Memorial Centre, Homi Bhabha National Institute, Department of Radiation Oncology, Mumbai, India.ORCID 0009-0008-3280-1802
Shivani SableTata Memorial Centre, Homi Bhabha National Institute, Department of Radiation Oncology, Mumbai, India.ORCID 0009-0006-0819-776X
Tabassum WadasadawalaTata Memorial Centre, Homi Bhabha National Institute, Department of Radiation Oncology, Mumbai, India.ORCID 0000-0003-2167-420X
Rajiv SarinTata Memorial Centre, Homi Bhabha National Institute, Department of Radiation Oncology, Mumbai, India.ORCID 0000-0002-6405-8282
Rima PathakTata Memorial Centre, Homi Bhabha National Institute, Department of Radiation Oncology, Mumbai, India.ORCID 0000-0002-4887-7130
Revathy KrishnamurthyTata Memorial Centre, Homi Bhabha National Institute, Department of Radiation Oncology, Mumbai, India.ORCID 0000-0003-2273-6847
Shalaka JoshiTata Memorial Centre, Homi Bhabha National Institute, Department of Surgical Oncology, Mumbai, India.ORCID 0000-0003-3813-4680
Vinaykant ShankhdharTata Memorial Centre, Homi Bhabha National Institute, Department of Plastic and Reconstructive Surgery, Mumbai, India.ORCID 0000-0002-1775-9967
Dushyant JaiswalTata Memorial Centre, Homi Bhabha National Institute, Department of Plastic and Reconstructive Surgery, Mumbai, India.ORCID 0000-0003-0457-8988
Saumya MathewsTata Memorial Centre, Homi Bhabha National Institute, Department of Plastic and Reconstructive Surgery, Mumbai, India.ORCID 0000-0003-0691-2660
Mayur MantriTata Memorial Centre, Homi Bhabha National Institute, Department of Plastic and Reconstructive Surgery, Mumbai, India.ORCID 0000-0003-0396-3526

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Post-mastectomy breast reconstruction improves body image and quality of life for women with breast cancer. Most adverse events emerge within the first 90 days and may contribute to long-term morbidity. This study prospectively evaluated the incidence and predictors of early complications following immediate autologous breast reconstruction in women with locally advanced breast cancer. Materials and Methods: Prospective data from a randomized controlled trial (CTRI/2017/01/007745) involving women undergoing immediate autologous whole breast reconstruction were analysed. Breast and donor-site complications were recorded and graded using Clavien-Dindo classification over 0-30 and 31-90 days. Univariate and multivariate analyses were performed to identify risk factors. Results: A total of 160 patients were included. The mean age was 37±7 years; body mass index (BMI) was 25.7±4.6; 25.6% had comorbidities. Deep inferior epigastric perforator (DIEP) flaps accounted for 85% of reconstructions. Within 0-30 days, 45% developed primary‑site complications; 33% developed donor‑site complications. At 31-90 days, primary‑site complications were reduced to 15%, and donor‑site complications to 13%. Re‑exploration was required in 11%; however, no flap loss was observed. Univariate analysis showed age >37, BMI ≥25, diabetes, multiple comorbidities, any comorbidity, and DIEP increased primary-site complication risk and BMI ≥25 and DIEP predicted donor‑site events. Multivariate analysis confirmed multiple comorbidities and DIEP as predictors of primary‑site complications, while BMI ≥25 and DIEP predicted donor‑site complications. As DIEP flaps predominated, in our patients technique-based comparisons should be interpreted cautiously. Conclusion: Immediate autologous whole-breast reconstruction in patients with advanced breast cancer undergoing multimodal therapy, including intensive chemotherapy and radiotherapy, resulted in a high overall complication rate but no reconstructive failures, highlighting the need for a selective, individualized approach with comprehensive preoperative counselling and shared decision-making.

Indexed as

acute complicationsautologous reconstructionbreast cancerbreast reconstructionSurgical complications

Identifiers

PMID42316940
PMCPMC13280612

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.